Metformin therapy lowers plasma levels of asymmetric dimethylarginine (ADMA) in hyperglycaemic patients with type 2 diabetes.
Previous studies observed a significant relationship between insulin resistance and plasma concentrations of ADMA and that elevated plasma ADMA levels may contribute to endothelial dysfunction observed in insulin-resistant patients.
Researchers, at Stanford University School of Medicine in Stanford, California in the United States, found that patients treated with metformin, either as monotherapy or with sulfonylurea, had a favourable increase in their ratio of plasma L-arginine-to-ADMA ratio.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!